The induction of angiogenesis as a therapeutic strategy for both coronary and peripheral arterial disease has been investigated in a series of clinical randomised clinical trials, primarily using vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF) as the proangiogenic transgene. This evidence concerns the gene VEGFA and peripheral arterial disease.